Latest news with #ScotchMcClure
Globe and Mail
17-07-2025
- Business
- Globe and Mail
Maxwell Biosciences Announces AI Department & Hiring of Jon McClure
New leadership to spearhead AI-driven breakthroughs in drug discovery and operational excellence Austin, Texas--(Newsfile Corp. - July 17, 2025) - Maxwell Biosciences ("Maxwell"), a global health technology company pioneering immune-inspired small molecules called Claromers™, today announced new engineering leadership for its Artificial Intelligence efforts—further cementing its decade-long commitment to AI-first innovation. As part of this initiative, the company has appointed Jon McClure as Chief Technology Officer to accelerate the development of its AI-native platform for drug discovery and AI-empowered medical devices. To view an enhanced version of this graphic, please visit: "The future of medicine requires scalable intelligence, and Jon brings exactly that—combined with deeply human values," said Maxwell Biosciences CEO, Founder & Chairman Scotch McClure. "Our AI division will serve as both accelerator and amplifier—driving faster drug design, analyzing clinical trial data and infusing every part of Maxwell with AI." Maxwell is an AI-native organization since its founding in 2016 where intelligent systems are woven into the company's core—designing molecules, modeling human biology and accelerating business operations in real time. Every AI initiative is built with a singular goal: to speed up scientific discovery and translate it into health solutions that create health for the world, safely and affordably. At Maxwell, AI agents act as collaborators. They generate novel Claromer™ structures, predict how those compounds behave in the body and coordinate the tasks needed to move breakthroughs forward. These systems learn continuously, adapt to new data in real-time and operate with the same mission focus as the human teams they work alongside. Inspired by the cooperative logic of immune systems, Maxwell's AI architecture is decentralized, adaptive and deeply aligned with the biology it's helping to transform. The result is a faster, more resilient path from discovery to deployment—designed to meet the global demand for stable, shelf-ready and microbiome-safe anti-infectives. About Jon McClure Jon McClure is a seasoned technology leader with over 20 years of experience in software architecture; systems engineering; and team leadership across biotech, healthcare and gaming sectors. He has led multiple development and DevOps teams managing global high-availability environments. In his last role, he successfully transitioned global infrastructure to a Kubernetes-based architecture to improve scalability and reliability. He directed the nationwide deployment of a mission-critical, HIPAA-compliant patient management system for a major U.S. healthcare network, ensuring operational continuity across more than 150 hospitals during the COVID-19 pandemic. During this time, he also served as the lead engineer on and Jon brings deep expertise in full-stack development, microservices, cloud platforms and DevOps practices to his role as CTO. "Maxwell Biosciences is committed to pioneering the future of medicine through strategic investment in Artificial Intelligence, and I couldn't be more excited to lead that effort," said Maxwell Biosciences CTO, Jon McClure. "AI, when thoughtfully applied, will dramatically accelerate drug discovery, personalize treatment and ultimately create a healthier world. Using my background building high-availability cloud environments and developing large-scale software applications for organizations like the U.S. Department of Veterans Affairs, HHS and BARDA, our focus will be on building robust, AI-driven solutions that address critical challenges in infectious disease and beyond." About Maxwell Biosciences Maxwell Biosciences is a global health technology company pioneering a new category of immune-inspired small molecules called Claromers™. Designed to mimic the body's natural defenses, Claromers™ destroy pathogenic bacteria, viruses, fungi and biofilms—without harming healthy cells or the microbiome. Originally developed for critical infectious diseases, Maxwell's technology is now entering commercial deployment across cosmetics, personal care, medical coatings and biodefense. Claromers™ require no refrigeration and are highly stable in even the harshest environments. Backed by a decade of research, a robust patent portfolio and leadership with deep expertise in science, military, AI and global health, Maxwell has active partnerships with the US military and governments worldwide. FDA clinical trials are planned for 2026. Non-pharmaceutical commercialization begins in 2025, with pilot access with select partners already underway. Maxwell's AI-first platform enables rapid innovation against the rising threat of resistant pathogens, offering scalable, shelf-stable and microbiome-resilient solutions for a healthier planet. To learn more about Maxwell Biosciences, visit or follow us on X and LinkedIn.
Associated Press
23-04-2025
- Health
- Associated Press
Maxwell Biosciences Secures Anti-Diarrheal US Military Agreement
Maxwell's 7th signed US military agreement is for in vitro testing of Maxwell's Claromers for the treatment of diarrheal pathogens Austin, Texas--(Newsfile Corp. - April 23, 2025) - Maxwell Biosciences, a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the natural immune system, today announced a new collaboration. Maxwell has entered into a Limited Purpose Cooperative Research and Development Agreement (LP-CRADA) with the U.S. Naval Medical Research Command's (NMRC) Deployment Associated Infections Division (DAID) laboratory to conduct in vitro testing of Claromers™ for treatment and prevention of diarrheal illness. This agreement marks the 7th signed U.S. military agreement for Maxwell. [ This image cannot be displayed. Please visit the source: ] To view an enhanced version of this graphic, please visit: Diarrheal diseases remain the most pervasive infectious threat to U.S. military operational readiness [ 1 ]. The majority of cases result from increasingly drug-resistant strains of bacteria causing debilitating outbreaks that cripple mission effectiveness. During Operation Iraqi Freedom (OIF), 76% of warfighters experienced diarrheal episodes. Diarrheal diseases outpaced respiratory illnesses and injuries as the top non-combat medical issue [ 2 ]. In field conditions, even a single episode of diarrhea can sideline a soldier for days, impairing unit performance and mission success. 80% of cases require antibiotics or IV fluids [ 3 ]. Chronic post-infection complications like irritable bowel syndrome (15-30% of cases) and reactive arthritis further degrade long-term readiness [ 4 ]. As antibiotic resistance continues to rise, traditional treatments are losing efficacy, making preventive options and new therapeutic approaches an urgent priority. The impact isn't limited to the battlefield: travelers, humanitarian responders and civilians in low-resource settings also face similar risks, underscoring the need for globally relevant solutions. 'This partnership isn't just about stopping pathogens; it's about keeping our forces mission-ready and preventing critical situations from going down the drain. With Claromers™, we're determined to flush out antibiotic resistance and ensure troops aren't bogged down by debilitating illnesses,' said Scotch McClure, Founder & CEO of Maxwell Biosciences. About NMRC NMRC, headquarters of Navy Medicine Research & Development, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps, and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. About DAID Part of NMRC's Operationally Relevant Infections Department, DAID focuses on the advancement of both prophylactic vaccine and immunoprophylaxis products against Campylobacter, ETEC and Shigella mediated diseases that affect the warfighter. About Maxwell Biosciences Founded in 2016, Maxwell Biosciences is a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the natural immune system. Inspired by nature, these deep tech breakthrough molecules have been shown to be effective against Ebola, pan-coronavirus and pan-Influenza A (avian, swine and human) in destroying viruses, but also all tested bacteria, fungi and biofilms with a single compound, while safely preserving healthy cells. This new 'One Drug for Many Bugs' technology has been shown to be well-tolerated in lab-grown human tissues and in multiple animal studies and is shelf-stable. The compounds imitate key components of the innate immune system: humanity's greatest asset in fighting disease. Maxwell's technology is protected by numerous granted and pending patents and is led by a world-class team of scientists, military veterans and experienced life science executives. For more information, visit or follow us on X and LinkedIn. Contacts Media [email protected] Investors [email protected] Disclaimer The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government. To view the source version of this press release, please visit
Globe and Mail
05-03-2025
- Health
- Globe and Mail
Maxwell Biosciences Secures US Military Agreement to Research Scientific Aspects of Claromer Technology
U.S. Army Institute of Surgical Research to conduct key studies intended to further our knowledge of the effects of Claromer technology Austin, Texas--(Newsfile Corp. - March 5, 2025) - Maxwell Biosciences, a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the natural immune system, today announced a new collaboration. Maxwell has entered into a Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research (USAISR). Using their research experience and resources, the U.S. Army will conduct studies to support development of Maxwell's therapeutics that will treat viral, bacterial and fungal threats. This agreement marks the sixth research agreement between Maxwell and U.S. military branches. USAISR's laboratory will initially conduct in vitro studies with potential subsequent in vivo safety studies to explore core scientific aspects of Claromers TM. These studies will provide both the U.S. Army and Maxwell with crucial data needed for safe drug development. This research collaboration between the U.S. Army and Maxwell offers a unique opportunity to enhance treatment options for priority pathogens, especially for those lacking vaccines or therapies. If successful, Maxwell's drug pipeline could improve outcomes for warfighters and civilians. "The Claromer TM family of compounds represents a novel breakthrough," said Scotch McClure, CEO of Maxwell Biosciences. "We're delighted that the U.S. Army is as equally motivated as we are to research fundamental scientific aspects of these compounds. There's so much we can learn by working hand-in-hand with military scientists." About USAISR USAISR is focused on optimizing care for combat-injured patients. The USAISR Burn Center provides specialty care for burn and burn-like injuries. As the Department of Defense's primary laboratory, USAISR partners with hundreds of academic, industry and allied nation military laboratories. About Maxwell Biosciences Founded in 2016, Maxwell Biosciences is a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the natural immune system. Inspired by nature, these deep tech breakthrough molecules have been shown to be effective against Ebola, pan-coronavirus and pan-Influenza A (avian, swine and human) in destroying viruses, but also all tested bacteria, fungi and biofilms with a single compound, while safely preserving healthy cells. This new "One Drug for Many Bugs" technology has been shown to be well-tolerated in lab-grown human tissues and in multiple animal studies and is shelf-stable. The compounds imitate key components of the innate immune system: humanity's greatest asset in fighting disease. Maxwell's technology is protected by numerous granted and pending patents and is led by a world-class team of scientists, military veterans and experienced life science executives. For more information, visit or follow us on X and LinkedIn. Disclaimer The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government. To view the source version of this press release, please visit
Associated Press
05-03-2025
- Health
- Associated Press
Maxwell Biosciences Secures US Military Agreement to Research Scientific Aspects of Claromer Technology
U.S. Army Institute of Surgical Research to conduct key studies intended to further our knowledge of the effects of Claromer technology Austin, Texas--(Newsfile Corp. - March 5, 2025) - Maxwell Biosciences, a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the natural immune system, today announced a new collaboration. Maxwell has entered into a Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research (USAISR). Using their research experience and resources, the U.S. Army will conduct studies to support development of Maxwell's therapeutics that will treat viral, bacterial and fungal threats. This agreement marks the sixth research agreement between Maxwell and U.S. military branches. To view an enhanced version of this graphic, please visit: USAISR's laboratory will initially conduct in vitro studies with potential subsequent in vivo safety studies to explore core scientific aspects of Claromers TM. These studies will provide both the U.S. Army and Maxwell with crucial data needed for safe drug development. This research collaboration between the U.S. Army and Maxwell offers a unique opportunity to enhance treatment options for priority pathogens, especially for those lacking vaccines or therapies. If successful, Maxwell's drug pipeline could improve outcomes for warfighters and civilians. 'The Claromer TM family of compounds represents a novel breakthrough,' said Scotch McClure, CEO of Maxwell Biosciences. 'We're delighted that the U.S. Army is as equally motivated as we are to research fundamental scientific aspects of these compounds. There's so much we can learn by working hand-in-hand with military scientists.' About USAISR USAISR is focused on optimizing care for combat-injured patients. The USAISR Burn Center provides specialty care for burn and burn-like injuries. As the Department of Defense's primary laboratory, USAISR partners with hundreds of academic, industry and allied nation military laboratories. About Maxwell Biosciences Founded in 2016, Maxwell Biosciences is a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the natural immune system. Inspired by nature, these deep tech breakthrough molecules have been shown to be effective against Ebola, pan-coronavirus and pan-Influenza A (avian, swine and human) in destroying viruses, but also all tested bacteria, fungi and biofilms with a single compound, while safely preserving healthy cells. This new 'One Drug for Many Bugs' technology has been shown to be well-tolerated in lab-grown human tissues and in multiple animal studies and is shelf-stable. The compounds imitate key components of the innate immune system: humanity's greatest asset in fighting disease. Maxwell's technology is protected by numerous granted and pending patents and is led by a world-class team of scientists, military veterans and experienced life science executives. Contacts Media Disclaimer The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.
Globe and Mail
26-02-2025
- Health
- Globe and Mail
Maxwell Biosciences Secures US Military Research Agreement to Combat Dengue Fever
U.S. Naval Infectious Diseases Diagnostic Laboratory to study dengue fever activity of Claromer antiviral compounds, combatting a rapidly growing mosquito-borne viral infection and a national priority biodefense threat Austin, Texas--(Newsfile Corp. - February 26, 2025) - Maxwell Biosciences, a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the compounds of the human immune system, today announced a new collaboration. Maxwell has entered into a Cooperative Research and Development Agreement to develop therapies for dengue virus infections with the Naval Medical Research Command's (NMRC) Naval Medical Infectious Diseases Diagnostic Laboratory (NIDDL). Scientist examines dengue virus in laboratory To view an enhanced version of this graphic, please visit: Located at NMRC's Silver Spring, Maryland headquarters, the NIDDL assists in the detection and identification of high-risk and emerging infectious diseases and will test Maxwell Biosciences' Claromer TM compounds for use as an antiviral therapeutic agent against the four known strains of dengue fever, a mosquito-borne viral infection. "Entering a collaborative research and development agreement with the NMRC and NIDDL demonstrates the remarkable momentum behind Maxwell's Claromer™ biodefense technology," said Scotch McClure, CEO of Maxwell Biosciences. "Dengue fever cases continue to increase worldwide, with 12 million infections reported by the Centers for Disease Control in 2024 in the Americas. Globally, cases of dengue have doubled each year since 2021. At Maxwell, we're honored to partner with the U.S. military to tackle the most difficult diseases that are beyond the capabilities of other pharmaceutical companies. Maxwell is a true pioneer in this space, leading the world in our efforts for developing new, shelf-stable therapeutics against the world's most neglected, dangerous and deadly pathogens." About Dengue Dengue fever is categorized as a Neglected Tropical Disease by the World Health Organization. Dengue virus primarily passes to people from the bite of an infected Aedes species mosquito, the same mosquitos that carry Zika and Chikungunya. [ 1 ] Symptoms of dengue fever include high fever, severe headaches, pain behind the eyes, muscle and joint pain, nausea, vomiting, swollen glands, rash and death. Most cases are mild and last about two weeks. Severe dengue has more serious symptoms and often impacts those who are infected with dengue more than once. [ 2 ] Dengue is now the fastest-growing mosquito-borne illness in the world. [ 3 ] Between January and September 2024, 12.7 million cases were reported-double the total for all of 2023—with the highest concentration in the Americas. This surge is due in part to expanding mosquito habitats resulting from climate change. Dengue is endemic in 130 countries. [ 4 ] About the NMRC NMRC is engaged in a broad spectrum of activities, such as basic science in the laboratory, field studies in austere and remote areas of the world and investigations in operational environments. In support of the Navy, Marine Corps and joint U.S. warfighters, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, medical modeling, simulation, operational mission support, epidemiology and behavioral sciences. NMRC's NIDDL serves in the detection and identification of high-risk and emerging infectious diseases. It also conducts surveillance efforts for Department of Defense frontline providers and public health professionals in support of health protection for active-duty military members and military health system beneficiaries. About Maxwell Biosciences Founded in 2016, Maxwell Biosciences is a preclinical drug platform company that develops Claromers TM, synthetic small molecules that mimic and improve upon the natural immune system. Inspired by nature, these deep tech breakthrough molecules have been shown to be effective against Ebola, zika, herpes, dengue, pan-coronavirus and pan-influenza A (avian, swine and human) in destroying viruses, but also all tested bacteria, fungi and biofilms with a single compound, while safely preserving healthy cells. This new "One Drug for Many Bugs" technology has been shown to be well-tolerated in lab-grown human tissue and in multiple animal studies and is shelf-stable. The compounds imitate key components of the innate immune system: humanity's greatest asset in fighting disease. Maxwell's technology is protected by numerous granted and pending patents and is led by a world-class team of scientists, military veterans and experienced life science executives. Disclaimer The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.
